Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tepnel Life Sciences (UK) reports reduced net loss:

This article was originally published in Clinica

Executive Summary

Tepnel Life Sciences (UK) has reduced its loss to £890,000 ($1.4 million) in the half-year to the end of March from £1.01 million a year earlier. Anthony Martin, chairman since February, believes the company has sufficient financial resources to support its plans for the rest of 1995. Tepnel intends to concentrate on the introduction of its DNA technology in the genetic and cancer testing markets. The company says it is developing Solid Phase Amplification (SPA), a new method of DNA detection as an extension to its DARAS technology, for automated identification of DNA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT091833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel